Cambridge, MA – Jan 10 2025
XtalPi Inc. (HKEX: 2228.HK), a leader in AI-powered pharmaceutical technology, announced a strategic licensing agreement with UCB (Euronext: UCB), a global biopharmaceutical company, to accelerate next-generation biologic drug discovery. The collaboration grants UCB access to XtalPi’s proprietary XtalFold™ AI platform, an advanced solution for macromolecular drug discovery and engineering.
Revolutionizing Biologic Development with AI
The XtalFold™ platform integrates AI-driven predictive modeling with automation to enhance the accuracy and efficiency of biologic drug discovery. Key capabilities include:
- Antigen design & epitope mapping – Enabling precise target identification for biologic therapies.
- Affinity maturation strategies – Optimizing binding strength and therapeutic efficacy.
- pH-sensitive modification – Enhancing stability and bioavailability.
- Bispecific antibody engineering – Advancing novel modalities in therapeutic antibodies.
Validated through rigorous benchmarking, XtalFold™ has demonstrated industry-leading performance in modeling complex antibody-antigen interactions, addressing a key challenge in monoclonal antibody development.
Strategic Collaboration to Drive Innovation
The partnership underscores a shared commitment to leveraging AI in biologic drug development. UCB will deploy XtalFold™ to identify and optimize high-quality antibody candidates with unprecedented speed and precision.
“UCB exemplifies how computational approaches can drive differentiated therapeutics. We’re honored to empower their R&D with AI-driven structural insights that accelerate life-changing discoveries.”
— Dr. Jian Ma, CEO of XtalPi
“Following the Nobel Prize recognition for protein structure prediction, XtalFold™ represents industrialized deployment of this breakthrough. As a fully validated solution, it’s becoming the new standard across biologics development.”
— Daniel Lightwood, Head of Antibody Discovery at UCB
“After exhaustive comparative testing, we’re confident XtalFold™ will enhance our ability to rapidly identify high-quality antibody candidates, ultimately delivering novel therapies to patients faster.”
— Dr. Alexander Hillisch, Global Head of CADD at UCB
AI’s Expanding Role in Biopharma
This collaboration highlights the transformative impact of AI and computational modeling in biologic drug discovery. By integrating AI with deep domain expertise, XtalPi and UCB are positioned to redefine the speed and precision of antibody development, paving the way for novel therapies that address unmet medical needs.
About XtalPi
XtalPi is a leading AI-driven pharmaceutical technology company that leverages AI, quantum mechanics, and robotic automation to accelerate drug discovery and development. With a global presence and collaborations with over 200 pharmaceutical and biotech companies, XtalPi is advancing the next generation of therapeutics.
More about news
By